Clinical Trial Update: An Open Label Study of the Effects of Eculizumab in CD59 Deficiency [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 study evaluating the effects of eculizumab in CD59 deficiency presenting with chronic hemolysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cd59 Deficiency
• Hemolysis

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Chronic Hemolysis | Phase 1, Phase 2 | Status: UNKNOWN